Literature DB >> 8899777

Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis.

S Silverman1, J W Gallo, M L McKnight, P Mayer, S deSanz, M M Tan.   

Abstract

Eighty-five consecutively seen HIV-positive persons with oral candidiasis were evaluated for clinical characteristics, staging of HIV disease, quantitation of candidal colony formation, and response to systemic antifungal treatment with Nizoral (ketoconazole). Fifty-five had CD4 counts less than 200. There was an inconsistent association between clinical signs, patient symptoms, CD4 counts, and candidal colony-forming units. However, there was a trend toward higher colony-forming unit counts (> 500) in patients with lower CD4 cells (< 200). Sixty-five patients had a complete clinical response to the ketoconazole treatment (200 mg daily for 7 days), even though 81% of posttreatment cultures remained positive. Nonsmokers were more likely to respond to antifungal treatment when compared with smokers, and there was a slight tendency for complete responses when colony-forming unit counts were low. The most common lesion presentation was a combination of the white (pseudomembranous) and red (erythematous) forms. Forty-nine percent had complaints of pain. The variable responses indicated the importance of flexible dose-time and drug considerations in antifungal management. Candida albicans was the predominant species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899777     DOI: 10.1016/s1079-2104(96)80304-0

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  6 in total

1.  UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Authors:  Erin M Vasicek; Elizabeth L Berkow; Stephanie A Flowers; Katherine S Barker; P David Rogers
Journal:  Eukaryot Cell       Date:  2014-03-21

Review 2.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

3.  Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China.

Authors:  Haiyan Sun; Yong Chen; Xuan Zou; Huan Li; Xiuyun Yin; Haifeng Qin; Rongrui Liu; Changlin Yu; Qihong Li; Kaitao Yu; Xuelin Han; Jingcai Zou; Cheng Ge; Li Han
Journal:  Clin Oral Investig       Date:  2015-07-30       Impact factor: 3.573

4.  A study of antifungal drug sensitivity of Candida isolated from human immunodeficiency virus infected patients in Chennai, South India.

Authors:  Nadeem Jeddy; K Ranganathan; Uma Devi; Elizabeth Joshua
Journal:  J Oral Maxillofac Pathol       Date:  2011-05

5.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28

6.  Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

Authors:  Jose A Vazquez
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.